Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer

NCT02000947 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02000947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02000947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Completed
Start date
October 25, 2013
Completion date
September 17, 2019
Enrollment
459 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-small cell lung cancer, nsclc